Alaunos Therapeutics, Inc.
TCRT
$3.69
$0.133.65%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 6.00K | 6.00K | 10.00K | 9.00K | 6.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 6.00K | 6.00K | 10.00K | 9.00K | 6.00K |
| Cost of Revenue | 915.00K | 589.00K | 584.00K | 363.00K | 1.38M |
| Gross Profit | -909.00K | -583.00K | -574.00K | -354.00K | -1.38M |
| SG&A Expenses | 3.16M | 3.45M | 3.59M | 4.46M | 6.04M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.08M | 4.04M | 4.17M | 4.82M | 7.42M |
| Operating Income | -4.07M | -4.04M | -4.16M | -4.81M | -7.42M |
| Income Before Tax | -4.03M | -3.99M | -4.07M | -4.68M | -11.78M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -4.03 | -3.99 | -4.07 | -4.68 | -11.78 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.03M | -3.99M | -4.07M | -4.68M | -11.78M |
| EBIT | -4.07M | -4.04M | -4.16M | -4.81M | -7.42M |
| EBITDA | -4.07M | -4.03M | -4.16M | -4.81M | -7.17M |
| EPS Basic | -2.29 | -2.46 | -2.54 | -2.92 | -7.36 |
| Normalized Basic EPS | -1.43 | -1.54 | -1.59 | -1.83 | -2.81 |
| EPS Diluted | -2.29 | -2.46 | -2.54 | -2.92 | -7.36 |
| Normalized Diluted EPS | -1.43 | -1.54 | -1.59 | -1.83 | -2.81 |
| Average Basic Shares Outstanding | 7.06M | 6.48M | 6.40M | 6.40M | 6.40M |
| Average Diluted Shares Outstanding | 7.06M | 6.48M | 6.40M | 6.40M | 6.40M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |